Oncology Clinical Trials Market Report 2026

The oncology clinical trials market size has grown strongly in recent years. It will grow from $14.99 billion in 2025 to $15.98 billion in 2026 at a compound annual growth rate (CAGR) of 6.6%. The growth in the historic period can be attributed to limited treatment options for cancer patients, increasing incidence of cancer globally, growing pharmaceutical and biotech R&D investments, rising number of academic clinical research centers, increasing awareness of clinical trial importance.

The oncology clinical trials market size is expected to see strong growth in the next few years. It will grow to $20.4 billion in 2030 at a compound annual growth rate (CAGR) of 6.3%. The growth in the forecast period can be attributed to development of personalized oncology therapies, expansion of multicenter and global trials, adoption of digital patient monitoring tools, integration of AI and big data in trial design, increasing government and private funding for oncology research. Major trends in the forecast period include expansion of immunotherapy and targeted therapy clinical trials, growing focus on multicenter and randomized controlled trials, increased investment in post-marketing surveillance and long-term safety studies, rising adoption of cell and gene therapy trials, integration of biomarker and pharmacogenomics studies in oncology research.

The rising cancer incidence is anticipated to fuel the oncology clinical trials market moving forward. Cancer incidence measures new cases arising in a given population over a set timeframe. This upsurge largely arises from detrimental lifestyle choices like suboptimal nutrition, sedentary behavior, smoking, and heavy drinking, which heighten vulnerability to diverse cancers. Oncology clinical trials propel cancer care by assessing novel treatments and strategies, refining patient results via rigorous evidence. They hasten therapeutic breakthroughs by validating safety and effectiveness, fostering advances in prevention, detection, and management. For example, in October 2025, the National Health Service (NHS), a UK public health body, disclosed 354,820 new cancer cases in 2023 - averaging 972 daily, a jump of 8,605 from 2022. Hence, the climbing cancer incidence is boosting the oncology clinical trials market.

Prominent players in the oncology clinical trials market are pioneering tech-forward tools like advanced bioinformatics platforms to sharpen data insights, hasten participant enrollment, and refine study results. Advanced bioinformatics platforms are intricate software setups employing computational methods and algorithms to gather, process, and decode intricate biological and clinical datasets for research and care. For instance, in September 2023, Deep 6 AI, a US healthcare tech firm, rolled out an AI-driven genomics module to expedite recruitment for precision medicine and oncology trials. It harnesses AI and natural language processing to pull structured and unstructured genomics info from electronic health records, facilitating instant detection and precise pairing of patients to genetic profiles. Researchers gain access to scan millions of records across over 19,000 genes and 30,000 mutations, dramatically speeding enrollment and streamlining trial protocols.

In September 2023, Coherus BioSciences Inc., a US biopharmaceutical company, bought Surface Oncology Inc. for $66.9 million. This purchase aims to fortify Coherus's immuno-oncology lineup, broaden its tumor microenvironment therapies, and amplify the clinical promise of its PD-1 inhibitor, toripalimab. Surface Oncology Inc. is a US clinical-stage immuno-oncology firm running trials for innovative cancer treatments.

Major companies operating in the oncology clinical trials market are Pfizer Inc., Johnson & Johnson, Merck And Co. Inc., AbbVie Inc., Bayer AG, Novartis International AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, GSK plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Boehringer Ingelheim GmbH, Regeneron Pharmaceuticals Inc., Genentech Inc., BeiGene Ltd., Seagen Inc.

North America was the largest region in the oncology clinical trials market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oncology clinical trials market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the oncology clinical trials market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the oncology clinical trials market by increasing the cost of imported biologics, lab equipment, and digital monitoring devices required for advanced trials. Segments such as immunotherapy, cell and gene therapy, and targeted therapy trials are most affected, particularly in North America and Europe, which rely heavily on imports. While tariffs have raised operational costs and slowed supply chains, they have also encouraged domestic manufacturing, investment in local R&D, and innovation in cost-effective oncology clinical trial solutions.

The oncology clinical trials market research report is one of a series of new reports that provides oncology clinical trials market statistics, including oncology clinical trials industry global market size, regional shares, competitors with a oncology clinical trials market share, detailed oncology clinical trials market segments, market trends and opportunities, and any further data you may need to thrive in the oncology clinical trials industry. This oncology clinical trials market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Oncology clinical trials are research studies conducted to evaluate new treatments, drugs, or approaches for preventing, detecting, or managing cancer in humans. These trials aim to assess the safety, efficacy, and potential side effects of interventions before they are widely adopted, thereby supporting improved clinical outcomes and advancing cancer care.

The main phases of oncology clinical trials include phase I, phase II, phase III, and phase IV. Phase I trials are early-stage studies primarily focused on evaluating the safety, tolerability, and optimal dosage of a new cancer therapy, while also examining how the drug is absorbed, distributed, metabolized, and excreted by the body. These trials employ various study designs, including interventional, observational, and expanded access protocols, and utilize therapeutic modalities such as immunotherapy, targeted therapy, chemotherapy, cell and gene therapy, and others. Phase I oncology trials target a range of cancer indications, including lung cancer, breast cancer, colorectal cancer, prostate cancer, hematologic malignancies, and more. Sponsors typically include pharmaceutical and biotechnology companies, academic and research institutions, government agencies, and other organizations involved in clinical research.

The oncology clinical trials market includes revenues earned by entities through designing and conducting cancer-related clinical research studies, providing patient recruitment and enrollment services, supplying oncology-specific laboratory testing and diagnostics, and managing data collection, monitoring, and regulatory compliance. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.